Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy [4]

BJU International

Volumn 86, Issue 6, 2000, Pages 757-

  Duggan, B ^a   Kelly, J ^a   Keane, P F ^a   Williamson, K ^a   Johnston, S R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN BCL 2;

APOPTOSIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CHEMOSENSITIVITY; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY;

EID: 0033780454     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00895-6.x     Document Type: Letter

References (3)

1. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy
2. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer
3. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells